“Metformin does not improve IDFS, OS, or other breast cancer [BC] outcomes in moderate/high risk estrogen receptor (ER)/PR-positive or ER/PR-negative breast cancer patients and should not be used as breast cancer treatment in those groups,” Pamela J. Goodwin, MD, ...
Breast cancer mortality (BCM) stratified for positive vs negative status of c-KIT (A, B and C), VEGFR2 (D, E and F) and PDGFRα (G, H and I) for all (A, D, G), non triple-neg...
Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.
Breast-conserving surgery IBTR: Ipsilateral breast tumor recurrence NP: New primary tumor TR: True local recurrence BCT: Breast-conserving therapy BCSS: Breast cancer-specific survival OS: Overall survival PFS: Progression-free survival TNBC: Triple-negative breast cancer ORR: Overall re...
This pictorial essay discusses breast... M Adejolu,L Huo,E Rohren,... - 《Ajr American Journal of Roentgenology》 被引量: 93发表: 2012年 False-Negative and False-Positive Results in FDG-PET and PET/CT in Breast Cancer PET and PET/CT has been used for the management of breast cancer...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...
Finally, the antibody was tested by IHC on fine needle breast biopsies. As shown in Figure 3D, the antibody detected a specific punctate or granular signal in the cytoplasm of cancer cells, while normal epithelial and stromal cells were negative. Figure 3. Generation of a specific anti-STARD3...
Omicron and its subvariants take longer to peak or to clear than earlier SARS-CoV-2 variants. (Prowell had recentlytweetedabout how a household member’s symptoms disappeared and rapid antigen test results turned negative after completion of a course of nirmatrelvir/ritonavir. A week later, thou...
Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the development of resistance to chemotherapy affecting over 30% of patients. New therapeutics and companion biomarkers are urgently needed. Recognizing the elevated expression
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal